TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03512457

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention
Description: Women view an educational poster in changing room, and they receive a brochure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Intervention
Description: Women view an educational poster in changing room, and they receive a brochure.
Study: NCT04066712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 200 mg
Description: Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 200 mg
Description: Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 200 mg
Description: Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
Study: NCT01202591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Tablet oral once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet oral twice daily
Study: NCT04066712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 200 mg
Description: Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
Study: NCT01557634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Overnight closed-loop insulin delivery
Description: Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Overnight closed-loop insulin delivery
Description: Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
Study: NCT03101111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK
Description: Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR-vaccine
Description: Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
Study: NCT03350269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information provision
Description: Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
Study: NCT02805270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reconciliation intervention
Description: medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
Study: NCT00483756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
Study: NCT00835029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole varnish
Description: Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole troches
Description: The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
Study: NCT02113800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Afinitor®)
Description: Formulation: 10 mg/day Route: oral (tablet)
Study: NCT03802058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 40mg/m2 for Injection weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=2 for Injection weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy
Description: Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
Study: NCT00910507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise counseling
Description: Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise training
Description: Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
Study: NCT02356809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen
Description: Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
Study: NCT00167778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transverse plane rotation adaptor pylon
Description: Potential future practice

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid pylon
Description: Current clinical practice
Study: NCT03660137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOLLI Localization
Description: All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
Study: NCT00755209

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid
Description: Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
Study: NCT02452931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 45 mg
Description: Subcutaneous injection
Study: NCT02989987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Exposure Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support
Description: A local counselors provides social support on demand.
Study: NCT05343468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MapHabit System
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study: NCT00763503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD 2027
Description: 3µg/g Oily Spray
Study: NCT02880696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular stimulation sequence
Description: Vibrotactile stimulation of the right hand with regular intervals and random omissions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random stimulation sequence
Description: Vibrotactile stimulation of the right hand with random intervals and random omissions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCS
Description: Near-infrared imaging of the neurovascular response in the left somatosensory cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCS
Description: Near-infrared imaging of the neurovascular response in the left somatosensory cortex
Study: NCT02375789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active RhinoChill
Description: The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RhinoChill
Description: The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
Study: NCT04124679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
Study: NCT00548652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE
Description: is a VA based multidesciplinary weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medical crisis councelling
Description: group counselling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE
Description: is a VA based multidesciplinary weight loss intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyphenidate
Description: methyphenidate will be used to treat apathy dose 10mg bid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE
Description: is a VA based multidesciplinary weight loss intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyphenidate
Description: methyphenidate will be used to treat apathy dose 10mg bid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medical crisis councelling
Description: group counselling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE
Description: is a VA based multidesciplinary weight loss intervention
Study: NCT04197310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg, intravenously, Day 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 40mg, orally, Daily for a 28 day cycle
Study: NCT03931135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section
Description: The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section
Description: The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped
Study: NCT03428919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
Study: NCT00588068

Intervention type: OTHER
Intervention: Tumor and Marrow Markers
Description: Tumor and Marrow Markers
Study: NCT00199043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Study: NCT02291653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath
Description: video-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath
Description: video-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct-laryngoscopy
Study: NCT03633500

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Placebo Comparator: Sterile water: 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Breastmilk
Description: Experimental: Breastmilk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours. independently sucks at breast, bottle or cup feed
Study: NCT00927641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen Patch
Description: Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Two placebo patches placed on target ankle once daily for 14 days
Study: NCT01202591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
Study: NCT04992533

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-duration tourniquet
Description: Tourniquet is used in arthroscopic exploration and high tibial osteotomy
Study: NCT02763683

Intervention type: RADIATION
Intervention: PiB and VAT
Description: There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.

Intervention type: RADIATION
Intervention: PiB and VAT
Description: There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
Study: NCT04427332

Intervention type: OTHER
Intervention: Investigation of smell and taste disorders
Description: The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
Study: NCT01718418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reference
Study: NCT03027544

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
Study: NCT01410617

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemodialysis
Description: 3 sessions hemodialysis before CABG
Study: NCT02553356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT2385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT2385
Study: NCT02711917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.5
Description: 0.5 MAC Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.5
Description: 0.5 MAC Sevoflurane
Study: NCT04992533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-duration tourniquet
Description: Tourniquet is only used for arthroscopic exploration
Study: NCT01233206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin pre-treatment and co-administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo pre-treatment and co-administration
Study: NCT02711917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.5
Description: 0.5 MAC Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.75
Description: 0.75 MAC Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.75
Description: 0.75 MAC Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 0.75
Description: 0.75 MAC Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 1.0
Description: 1.0 MAC Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC 1.0
Description: 1.0 MAC Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Etomidate consumption
Study: NCT04141176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiri+
Description: CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
Study: NCT03372941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalbavancin
Description: Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
Study: NCT02711917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Etomidate consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Etomidate consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Consumption of Rocuronium
Study: NCT05103852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: vigilant patient installed in the MRI with compatible ECG electrodes for synchronization and monitoring, blood pressure cuff for monitoring, cardiac antenna. Sterile drape over the femoral region, femoral local anesthesia, femoral venipuncture, Swan Ganz probe venous navigation (CE marking, MRI compatible at 1.5T) with balloon inflated with 2 cc of gadolinium, navigation under real time SSFP cine sequence.
Study: NCT03159260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theraworx
Description: Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.